Company intelligence / Profile preview
Guangzhou Baiyunshan Jingxiutang Pharmaceutical
Foshan, Guangdong, Chinajxt.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Manufactures finished pharmaceuticals in China. Recently received an FDA warning letter citing significant violations of current Good Manufacturing Practice regulations during a December 2023 inspection. Issues included inadequate laboratory controls and quality unit deficiencies.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeTraditional Chinese Medicine products
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Guangzhou Baiyunshan Jingxiutang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Baiyunshan Jingxiutang Pharmaceutical.